Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Sorbonne Université · AXA Research Fund · +56 more institutions
Abstract
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical…
Citation impact
- FWCI
- 108.35
- Percentile
- 100%
- References
- 302
Authors
35- BDBruno DuboisCorresponding
Sorbonne Université
- HHHarald Hampel
Sorbonne Université, AXA Research Fund
- HFHoward Feldman
University of British Columbia
- PSPhilip Scheltens
Amsterdam Neuroscience, Amsterdam UMC Location Vrije Universiteit Amsterdam
- PAPaul Aisen
University of Southern California, Southern States University
Topics & keywords
- Natural history
- Disease
- Natural (archaeology)
- Medicine
- History
- Pathology
- Internal medicine
- Good health and well-being
Funding
- CICalifornia Institute for Regenerative Medicine
- AAAlzheimer's Association
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- BBiogen
- FPFondation pour l'Aide à la Recherche sur la Sclérose en Plaques
- DDanone
- FBFondation Brain Canada
- NCNorthern California Institute for Research and Education
- LLLes Laboratories Pierre Fabre
- EJEU Joint Programme – Neurodegenerative Disease Research
- BFBundesinstitut für Arzneimittel und Medizinprodukte
- TPTauRx Pharmaceuticals
- NINational Institute for Health and Care ResearchAward: ES/L001810/1
- ANAgence Nationale de la RechercheAwards: ANR-10-IAIHU-06, 10-IAIHU-06, ANR-10
- ARAXA Research FundAward: ANR-10-IAIHU-06
- MDMinistero della SaluteAward: GR-2011-02350494
- EEisai
- VVetenskapsrådet
- FEFujirebio Europe
- UPUniversité Pierre et Marie Curie
- AFAssociation France Parkinson
- SServier
- HLH. Lundbeck A/S
- IIpsen
- FPFondation pour la Recherche sur Alzheimer
- NINational Institutes of HealthAwards: P50 AG05142, R01 AG037561, R01 AG033288, UF1 AG046148, AG05142, ANR-10-IAIHU-06
- GGenentech
- UOUniversity of California, San Diego
- MCMcDonnell Center for Systems Neuroscience
- ARAvid Radiopharmaceuticals
- TCTau Consortium
- CICanadian Institutes of Health Research
- EAEngineering and Physical Sciences Research CouncilAwards: EP/M006093/1, M006093
- EAEconomic and Social Research CouncilAwards: ES/L001810/1, ES/L001810/1
- CFCenter for Innovative Medicine
- NINational Institute on Aging
- JPJanssen Pharmaceuticals